Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yun-Kai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David Flowers, Marc Presler, Kalyanasundaram Subramanian, Jia Xue, Jingjing Wang, Kevin Lynch, Jay Mei, Xiaowen He, Bo Shan, Bing Hou
Immune checkpoint inhibitors (ICI) have transformed cancer treatment. However, only a minority of patients achieve a profound response. Many patients are innately resistant while others acquire resistance to ICIs. Furthermore, hepatotoxicity and suboptimal efficacy have hampered the clinical development of agonists of 4-1BB, a promising immune stimulating target. To effectively target 4-1BB and treat diseases resistant to ICIs, we engineered ATG-101, a tetravalent "2+2" PD-L1×4-1BB bispecific antibody...
March 19, 2024: Cancer Research